Event Recap: RAPS Utah/BioUtah Seminar – “Transitioning to New EU MDR & EU IVDR – Post-Market Surveillance, Clinical and Usability Studies” hosted by MasterControl
April 12, 2019
Approximately 90 attendees joined us on March 28, 2019 for this event, “Transitioning to New EU MDR & EU IVDR – Post-Market Surveillance, Clinical and Usability Studies,” hosted by MasterControl.
Participants were first able to hear from the following speakers:
* Robert Wolfarth, Chapter Chair of new RAPS Utah chapter; and Senior Manager, Regulatory Affairs, Merit Medical Systems, Inc.
* Kelvyn Cullimore, President and CEO of BioUtah
* Matt Lowe, EVP of Product, MasterControl
Following the opening remarks, three life sciences professionals spoke on a general overview of the situation; Post-Market Surveillance, Vigilance and Market Surveillance; Clinical Evaluation and Clinical Investigations; and the parallel chapters of the IVDR. The speakers were Dr. Michael Rinck, PhD (managing director, pharmacist and microbiologist, Promedt Consulting GmbH), Linda Chatwin, RAC, JD (senior customer solutions consultant, Health Sciences Division, Emergo, a UL Company), and Dr. Kristen Kanack, PhD (senior vice president, regulatory and clinical affairs, BioFire Diagnostics, LLC).
The event concluded with a Q & A session between the audience and the three featured speakers.
If you missed the seminar, please still feel free to contribute to the online RAPS discussion group to continue questions: https://connect.raps.org/utah/home
Recent News
- bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
- DGENTHERA AND NUSANO SIGN LETTER OF INTENT FOR ASTATINE‑211 SUPPLY
- 2025 BIO International Recap
- Halia Therapeutics Completes First-in-Human Phase 1 Study of HT-4253, a Novel LRRK2 Inhibitor Targeting Neuroinflammation
- Nelson Labs to Double Cleanroom Capacity to Support Growing Demand for Sterility Assurance Services
- RATIO THERAPEUTICS AND NUSANO ENTER LONG-TERM, MULTI-ISOTOPE SUPPLY AGREEMENT TO BOOST PRODUCTION OF CANCER RADIOPHARMACEUTICALS